Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.25) per share. This is a 525 percent decrease over losses of $(0.04) per share from the same period last year.
Credit Suisse Initiates Coverage On PerkinElmer with Neutral Rating, Announces Price Target of $175
Credit Suisse analyst Dan Leonard initiates coverage on PerkinElmer (NYSE:PKI) with a Neutral rating and announces Price Target of $175.